Understanding cachexia as a cancer metabolism syndrome

Oncogenesis

Volumn 5, Issue 2, 2016, Pages

  Porporato, P E ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARDIOLIPIN; GAMMA INTERFERON; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; LIPID; MICRORNA; PARATHYROID HORMONE RELATED PROTEIN; SOMATOMEDIN C;

CACHEXIA; CARDIAC MUSCLE; ENERGY EXPENDITURE; GLUCONEOGENESIS; HUMAN; LIPID STORAGE; MOLECULAR MECHANICS; MUSCLE ATROPHY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 84988696726     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2016.3     Document Type: Review

References (197)

1. Fearon KC, Glass DJ, Guttridge DC Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166.
2. Melstrom LG, Melstrom KA Jr, Ding XZ, Adrian TE. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 2007; 22: 805-814.
3. Argiles JM, Lopez-Soriano FJ, Toledo M., Betancourt A, Serpe R, Busquets S. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2011; 2: 87-93.
4. Johns N, Stephens NA, Fearon KC Muscle wasting in cancer. Int J Biochem Cell Biol 2013; 45: 2215-2229.
5. Houten L, Reilley AA An investigation of the cause of death from cancer. J Surg Oncol 1980; 13: 111-116.
6. Kalantar-Zadeh K., Rhee C, Sim J.J., Stenvinkel P., Anker SD, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4: 89-94.
7. Fearon KC, Baracos VE Cachexia in pancreatic cancer: new treatment options and measures of success. HPB (Oxford) 2010; 12: 323-324.
8. Vaughan VC, Martin P, Lewandowski PA Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013; 4: 95-109.
9. Evans WJ, Morley JE, Argiles J, Bales C., Baracos V, Guttridge D et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799.
10. Tisdale MJ. Wasting in cancer. J Nutr 1999; 129(Suppl 1): 243S-246S.
11. Argiles JM, Busquets S, Stemmler B., Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14: 754-762.
12. Vander Heiden M.G., Cantley LC, Thompson CB Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
14. Argiles JM, Lopez-Soriano FJ, Busquets S. Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 2012; 17: 253-262.
15. Mantovani G, Maccio A, Mura L., Massa E, Mudu MC, Mulas C et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med (Berl) 2000; 78: 554-561.
16. Torti FM, Dieckmann B, Beutler B., Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 1985; 229: 867-869.
17. Jakubowski AA, Casper ES, Gabrilove J.L., Templeton MA, Sherwin SA, Oettgen HF. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1989; 7: 298-303.
18. Han Y, Weinman S, Boldogh I., Walker RK, Brasier AR. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J Biol Chem 1999; 274: 787-794.
19. Monk JP, Phillips G, Waite R., Kuhn J, Schaaf LJ, Otterson GA et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006; 24: 1852-1859.
20. Jatoi A, Ritter HL, Dueck A, Nguyen P.L., Nikcevich DA, Luyun RF et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010; 68: 234-239.
21. Acharyya S, Ladner KJ, Nelsen L.L., Damrauer J., Reiser PJ, Swoap S et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370-378.
22. Flores EA, Bistrian BR, Pomposelli J.J., Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989; 83: 1614-1622.
23. Uehara A, Sekiya C, Takasugi Y., Namiki M, Arimura A. Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor. Am J Physiol 1989; 257: R613-R617.
24. Costelli P, Llovera M, Carbo N., Garcia-Martinez C, Lopez-Sorianoq FJ, Argiles JM. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett 1995; 95: 33-38.
25. Graziano F, Ruzzo A, Santini D., Humar B, Tonini G, Catalano V et al. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. J Clin Oncol 2005; 23: 2339-2345.
26. Baltgalvis KA, Berger FG, Pena M.M., Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 2008; 294: R393-R401.
27. Bonetto A, Aydogdu T, Kunzevitzky N., Guttridge DC, Khuri S, Koniaris LG et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2011; 6: e22538.
28. Kuroda K, Nakashima J, Kanao K., Kikuchi E, Miyajima A, Horiguchi Y et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007; 69: 113-117.
29. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004; 111: 592-595.
30. Henderson JT, Seniuk NA, Richardson P.M., Gauldie J., Roder JC. Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J Clin Invest 1994; 93: 2632-2638.
31. Seto DN, Kandarian SC, Jackman RW A key role for leukemia inhibitory factor in C26 cancer cachexia. J Biol Chem 2015; 290: 19976-19986.
32. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 2011; 668(Suppl 1): S81-S86.
33. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10: 90-99.
34. Lundholm K, Gelin J, Hyltander A., Lonnroth C, Sandstrom R, Svaninger G et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-5606.
35. Cerchietti LC, Navigante AH, Castro MA Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 2007; 59: 14-20.
36. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013; 6: 25-39.
37. Cohen S, Nathan JA, Goldberg AL Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2015; 14: 58-74.
38. Penna F, Bonetto A, Muscaritoli M., Costamagna D, Minero VG, Bonelli G et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer 2010; 127: 1706-1717.
39. Asp ML, Tian M, Wendel A.A., Belury MA. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 2010; 126: 756-763.
40. Costelli P, Muscaritoli M, Bossola M., Penna F, Reffo P, Bonetto A et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol 2006; 291: R674-R683.
41. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21: 129-137.
42. Garcia JM, Garcia-Touza M, Hijazi R.A., Taffet G., Epner D, Mann D et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920-2926.
43. Rofe AM, Bourgeois CS, Coyle P, Taylor A., Abdi EA. Altered insulin response to glucose in weight-losing cancer patients. Anticancer Res 1994; 14: 647-650.
44. Yoshida T, Delafontaine P. Mechanisms of cachexia in chronic disease states. Am J Med Sci 2015; 350: 250-256.
45. Nagaya N, Uematsu M, Kojima M., Date Y, Nakazato M, Okumura H et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104: 2034-2038.
46. Mantovani G, Maccio A, Madeddu C., Serpe R, Massa E, Dessi M et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15: 200-211.
47. Lokireddy S, Wijesoma IW, Bonala S, Wei M., Sze SK, McFarlane C et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J 2012; 446: 23-36.
48. Gallot YS, Durieux AC, Castells J, Desgeorges M.M., Vernus B., Plantureux L et al. Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res 2014; 74: 7344-7356.
49. Loumaye A, de Barsy M, Nachit M, Lause P., Frateur L, van Maanen A et al. Role of activin a and myostatin in human cancer cachexia. J Clin Endocrinol Metab 2015; 100: 2030-2038.
50. Zhou X, Wang JL, Lu J, Song Y., Kwak KS, Jiao Q et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-543.
51. Waning DL, Mohammad KS, Reiken S, Xie W., Andersson DC, John S et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med 2015; 21: 1262-1271.
52. Sun YS, Ye ZY, Qian Z.Y., Xu XD, Hu JF. Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J Exp Clin Cancer Res 2012; 31: 81.
53. Paul PK, Gupta SK, Bhatnagar S, Panguluri S.K., Darnay BG, Choi Y et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol 2010; 191: 1395-1411.
54. Figueroa-Clarevega A., Bilder D. Malignant Drosophila tumors interrupt insulin signaling to induce cachexia-like wasting. Dev Cell 2015; 33: 47-55.
55. Kwon Y, Song W, Droujinine I.A., Hu Y., Asara JM, Perrimon N. Systemic organ wasting induced by localized expression of the secreted insulin/IGF antagonist ImpL2. Dev Cell 2015; 33: 36-46.
56. Wagner EF, Petruzzelli M. Cancer metabolism: a waste of insulin interference. Nature 2015; 521: 430-431.
57. Lundholm K, Edstrom S, Ekman L., Karlberg I, Schersten T. Metabolism in peripheral tissues in cancer patients. Cancer Treat Rep 1981; 65(Suppl 5): 79-83.
58. Baar K, Nader G, Bodine S. Resistance exercise, muscle loading/unloading and the control of muscle mass. Essays Biochem 2006; 42: 61-74.
59. Bodine SC, Latres E, Baumhueter S., Lai VK, Nunez L, Clarke BA et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-1708.
60. Baracos VE, DeVivo C, Hoyle D.H., Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995; 268: E996-1006.
61. Schakman O, Kalista S, Barbe C., Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45: 2163-2172.
62. Temparis S, Asensi M, Taillandier D., Aurousseau E, Larbaud D, Obled A et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 1994; 54: 5568-5573.
63. Sandri M, Sandri C, Gilbert A., Skurk C, Calabria E, Picard A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
64. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-298.
65. Chacon-Cabrera A., Fermoselle C, Urtreger A.J., Mateu-Jimenez M, Diament MJ, de Kier Joffe ED et al. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J Cell Physiol 2014; 229: 1660-1672.
66. Bossola M, Muscaritoli M, Costelli P., Grieco G, Bonelli G, Pacelli F et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003; 237: 384-389.
67. Milan G, Romanello V, Pescatore F., Armani A, Paik JH, Frasson L et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat Commun 2015; 6: 6670.
68. Penna F, Costamagna D, Pin F., Camperi A, Fanzani A, Chiarpotto EM et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol 2013; 182: 1367-1378.
69. McClung JM, Judge AR, Powers S.K., Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010; 298: C542-C549.
70. Op den Kamp CM, Langen RC, Snepvangers F.J., de Theije CC, Schellekens JM, Laugs F et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 2013; 98: 738-748.
71. Tardif N, Klaude M, Lundell L., Thorell A, Rooyackers O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr 2013; 98: 1485-1492.
72. Boyer-Guittaut M., Poillet L, Liang Q., Bole-Richard E, Ouyang X, Benavides GA et al. The role of GABARAPL1/GEC1 in autophagic flux and mitochondrial quality control in MDA-MB-436 breast cancer cells. Autophagy 2014; 10: 986-1003.
73. Stephens NA, Skipworth RJ, Gallagher I.J., Greig CA, Guttridge DC, Ross JA et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 2015; 6: 53-61.
74. Costelli P, Reffo P, Penna F., Autelli R, Bonelli G, Baccino FM Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005; 37: 2134-2146.
75. He WA, Berardi E, Cardillo V.M., Acharyya S., Aulino P, Thomas-Ahner J et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 2013; 123: 4821-4835.
76. He WA, Calore F, Londhe P., Canella A, Guttridge DC, Croce CM Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci USA 2014; 111: 4525-4529.
77. Tzika AA, Fontes-Oliveira CC, Shestov A.A., Constantinou C., Psychogios N, Righi V et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int J Oncol 2013; 43: 886-894.
78. Antunes D, Padrao AI, Maciel E, Santinha D., Oliveira P, Vitorino R et al. Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting. Biochim Biophys Acta 2014; 1841: 896-905.
79. McLean JB, Moylan JS, Andrade FH Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes. Front Physiol 2014; 5: 503.
80. Bing C, Russell ST, Beckett E.E., Collins P., Taylor S, Barraclough R et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br J Cancer 2002; 86: 612-618.
81. Sanchis D, Busquets S, Alvarez B., Ricquier D, Lopez-Soriano FJ, Argiles JM. Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett 1998; 436: 415-418.
82. Collins P, Bing C, McCulloch P., Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 2002; 86: 372-375.
83. Divakaruni AS, Brand MD The regulation and physiology of mitochondrial proton leak. Physiology (Bethesda) 2011; 26: 192-205.
84. Nedergaard J, Ricquier D, Kozak LP Uncoupling proteins: current status and therapeutic prospects. EMBO Rep 2005; 6: 917-921.
85. Ushmorov A, Hack V, Droge W. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. Cancer Res 1999; 59: 3527-3534.
86. Barreiro E. Protein carbonylation and muscle function in COPD and other conditions. Mass Spectrom Rev 2014; 33: 219-236.
87. Argiles JM, Fontes-Oliveira CC, Toledo M., Lopez-Soriano FJ, Busquets S. Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 2014; 5: 279-286.
88. Zentella A, Manogue K, Cerami A. Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. Cytokine 1993; 5: 436-447.
89. Willis MS, Bevilacqua A, Pulinilkunnil T., Kienesberger P, Tannu M, Patterson C. The role of ubiquitin ligases in cardiac disease. J Mol Cell Cardiol 2014; 71: 43-53.
90. Tian M, Nishijima Y, Asp M.L., Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 2010; 37: 347-353.
91. Wysong A, Couch M, Shadfar S., Li L, Rodriguez JE, Asher S et al. NF-kappaB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol 2011; 178: 1059-1068.
92. Mustafa I, Leverve X. Metabolic and nutritional disorders in cardiac cachexia. Nutrition 2001; 17: 756-760.
93. Drott C, Lundholm K. Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. J Surg Res 1990; 49: 62-68.
94. Lieffers JR, Mourtzakis M, Hall K.D., McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009; 89: 1173-1179.
95. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-871.
96. Julienne CM, Tardieu M, Chevalier S., Pinault M, Bougnoux P, Labarthe F et al. Cardiolipin content is involved in liver mitochondrial energy wasting associated with cancer-induced cachexia without the involvement of adenine nucleotide translocase. Biochim Biophys Acta 2014; 1842: 726-733.
97. Dumas JF, Goupille C, Julienne C.M., Pinault M., Chevalier S, Bougnoux P et al. Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis. J Hepatol 2011; 54: 320-327.
98. Holroyde CP, Skutches CL, Boden G, Reichard GA Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 1984; 44: 5910-5913.
99. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410.
100. George A, Reichard J, Nelson I., Moury F, Norman JR, Hochella J et al. Quantitative estimation of the cori cycle in the human. J Biol Chem 1963; 238: 495-501.
101. Holroyde CP, Gabuzda TG, Putnam R.C., Paul P., Reichard GA. Altered glucose metabolism in metastatic carcinoma. Cancer Res 1975; 35: 3710-3714.
102. FENNINGER LD, MIDER GB Energy and nitrogen metabolism in cancer. Adv Cancer Res 1954; 2: 229-253.
103. Berriel DM, Krones-Herzig A, Metzger D., Ziegler A, Vegiopoulos A, Klingenspor M et al. Nuclear receptor cofactor receptor interacting protein 140 controls hepatic triglyceride metabolism during wasting in mice. Hepatology 2008; 48: 782-791.
104. Martignoni ME, Dimitriu C, Bachmann J., Krakowski-Rosen H, Ketterer K, Kinscherf R et al. Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol Rep 2009; 21: 363-369.
105. Jones A, Friedrich K, Rohm M., Schafer M, Algire C, Kulozik P et al. TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Mol Med 2013; 5: 294-308.
106. Sunny NE, Parks EJ, Browning J.D., Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011; 14: 804-810.
107. Patra SK, Arora S. Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome. Clin Chim Acta 2012; 413: 1025-1034.
108. Bologa RM, Levine DM, Parker T.S., Cheigh JS, Serur D, Stenzel KH et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
109. Brenner DA, Buck M, Feitelberg S.P., Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990; 85: 248-255.
110. Hennig B, Honchel R, Goldblum S.E., McClain CJ. Tumor necrosis factor-mediated hypoalbuminemia in rabbits. J Nutr 1988; 118: 1586-1590.
111. Fearon KC, Falconer JS, Slater C, McMillan D.C., Ross JA, Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg 1998; 227: 249-254.
112. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker S.J., Kamphorst JJ, Hackett S et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013; 497: 633-637.
113. Kamphorst JJ, Nofal M, Commisso C., Hackett SR, Lu W, Grabocka E et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 2015; 75: 544-553.
114. Costa G, HOLLAND JF Effects of Krebs-2 carcinoma on the lipide metabolism of male Swiss mice. Cancer Res 1962; 22: 1081-1083.
115. Das SK, Eder S, Schauer S., Diwoky C, Temmel H, Guertl B et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011; 333: 233-238.
116. Shaw JH, Wolfe RR Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann Surg 1987; 205: 368-376.
117. Das SK, Hoefler G. The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med 2013; 19: 292-301.
118. Russell ST, Tisdale MJ Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein. Endocrinology 2010; 151: 4696-4704.
119. Kir S, White JP, Kleiner S, Kazak L., Cohen P, Baracos VE et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 2014; 513: 100-104.
120. Petruzzelli M, Schweiger M, Schreiber R., Campos-Olivas R, Tsoli M, Allen J et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 2014; 20: 433-447.
121. Puigserver P, Wu Z, Park C.W., Graves R., Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-839.
122. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352: 373-379.
123. Carracedo A, Cantley LC, Pandolfi PP Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013; 13: 227-232.
124. DeWys WD. Changes in taste sensation and feeding behaviour in cancer patients: a review. J Hum Nutr 1978; 32: 447-453.
125. Martinez-Sanchez N., Alvarez CV, Ferno J, Nogueiras R., Dieguez C, Lopez M. Hypothalamic effects of thyroid hormones on metabolism. Best Pract Res Clin Endocrinol Metab 2014; 28: 703-712.
126. Anand BK, Pillai RV Activity of single neurones in the hypothalamic feeding centres: effect of gastric distension. J Physiol 1967; 192: 63-77.
127. Wang GJ, Tomasi D, Backus W., Wang R, Telang F, Geliebter A et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage 2008; 39: 1824-1831.
128. Moran TH, Dailey MJ Intestinal feedback signaling and satiety. Physiol Behav 2011; 105: 77-81.
129. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.
130. Laviano A, Russo M, Freda F., Rossi-Fanelli F. Neurochemical mechanisms for cancer anorexia. Nutrition 2002; 18: 100-105.
131. Otto B, Cuntz U, Fruehauf E., Wawarta R, Folwaczny C, Riepl RL et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145: 669-673.
132. Chance WT, Balasubramaniam A, Borchers M., Fischer JE. Refractory hypotha-lamic adenylate cyclase in anorectic tumor-bearing rats: implications for NPY-induced feeding. Brain Res 1995; 691: 180-184.
133. Chance WT, Xiao C, Dayal R., Sheriff S. Alteration of NPY and Y1 receptor in dorsomedial and ventromedial areas of hypothalamus in anorectic tumor-bearing rats. Peptides 2007; 28: 295-301.
134. Laviano A, Inui A, Marks D.L., Meguid MM, Pichard C, Rossi FF et al. Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab 2008; 295: E1000-E1008.
135. Silva VR, Micheletti TO, Pimentel G.D., Katashima CK, Lenhare L, Morari J et al. Hypothalamic S1P/S1PR1 axis controls energy homeostasis. Nat Commun 2014; 5: 4859.
136. Laviano A, Meguid MM, Inui A, Muscaritoli M., Rossi-Fanelli F. Therapy insight: cancer anorexia-cachexia syndrome - when all you can eat is yourself. Nat Clin Pract Oncol 2005; 2: 158-165.
137. Cahlin C, Gelin J, Delbro D., Lonnroth C, Doi C, Lundholm K. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 2000; 60: 1742-1749.
138. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg A.L., Hendrich TO et al. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 2004; 308: 929-934.
139. Feng P, Jyotaki M, Kim A., Chai J, Simon N, Zhou M et al. Regulation of bitter taste responses by tumor necrosis factor. Brain Behav Immun 2015; 49: 32-42.
140. Kluger MJ, Rothenburg BA Fever and reduced iron: their interaction as a host defense response to bacterial infection. Science 1979; 203: 374-376.
141. Cahlin C, Korner A, Axelsson H., Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000; 60: 5488-5493.
142. Bing C, Taylor S, Tisdale M.J., Williams G. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypo-thalamic neuropeptide Y. J Neurochem 2001; 79: 1004-1012.
143. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012; 22: 50-60.
144. Williams KW, Elmquist JK From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nat Neurosci 2012; 15: 1350-1355.
145. Grossberg AJ, Scarlett JM, Marks DL Hypothalamic mechanisms in cachexia. Physiol Behav 2010; 100: 478-489.
146. Tchekmedyian NS, Tait N, Moody M., Greco FA, Aisner J. Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol 1986; 13(Suppl 4): 37-43.
147. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992; 11: 445-456.
148. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer 1992; 52: 511-516.
149. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-336.
150. Glicksman AS, Rawson RW Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 1956; 9: 1127-1134.
151. Honors MA, Kinzig KP The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle 2012; 3: 5-11.
152. Parekh N, Lin Y, Hayes R.B., Albu JB, Lu-Yao GL. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 2010; 21: 631-642.
153. Fernandes LC, Machado UF, Nogueira C.R., Carpinelli AR, Curi R. Insulin secretion in Walker 256 tumor cachexia. Am J Physiol 1990; 258: E1033-E1036.
154. Hotamisligil GS, Murray DL, Choy L.N., Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-4858.
155. Brooks PC, Klemke RL, Schon S, Lewis J.M., Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 1997; 99: 1390-1398.
156. Massoner P, Ladurner-Rennau M, Eder I.E., Klocker H. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 2010; 103: 1479-1484.
157. Cullen KJ, Yee D, Sly W.S., Perdue J., Hampton B, Lippman ME et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990; 50: 48-53.
158. Maloney EK, McLaughlin JL, Dagdigian N.E., Garrett LM, Connors KM, Zhou XM et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083.
159. Gelfand RA, Barrett EJ Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest 1987; 80: 1-6.
160. Lecker SH, Solomon V, Price S.R., Kwon YT, Mitch WE, Goldberg AL. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest 1999; 104: 1411-1420.
161. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997; 66: 581-611.
162. Asp ML, Tian M, Kliewer K.L., Belury MA. Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther 2011; 12: 957-965.
163. Lundholm K, Korner U, Gunnebo L., Sixt-Ammilon P, Fouladiun M, Daneryd P et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13: 2699-2706.
164. Bartlett DL, Charland SL, Torosian MH Reversal of tumor-associated hyperglu-cagonemia as treatment for cancer cachexia. Surgery 1995; 118: 87-97.
165. Hartl WH, Demmelmair H, Jauch K.W., Koletzko B., Schildberg FW. Effect of glucagon on protein synthesis in human rectal cancer in situ. Ann Surg 1998; 227: 390-397.
166. Inculet RI, Peacock JL, Gorschboth C.M., Norton JA. Gluconeogenesis in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin, and glucagon. J Natl Cancer Inst 1987; 79: 1039-1046.
167. Puppa MJ, White JP, Sato S, Cairns M., Baynes JW, Carson JA. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta 2011; 1812: 1601-1606.
168. Klein GL, Petschow BW, Shaw A.L., Weaver E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr Opin Support Palliat Care 2013; 7: 361-367.
169. Bindels LB, Delzenne NM Muscle wasting: the gut microbiota as a new therapeutic target? Int J Biochem Cell Biol 2013; 45: 2186-2190.
170. Cani PD. Gut microbiota and obesity: lessons from the microbiome. Brief Funct Genomics 2013; 12: 381-387.
171. Bindels LB, Neyrinck AM, Salazar N, Taminiau B., Druart C, Muccioli GG et al. Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia in mice. PLoS ONE 2015; 10: e0131009.
172. Bindels LB, Porporato P, Dewulf E.M., Verrax J., Neyrinck AM, Martin JC et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 2012; 107: 1337-1344.
173. Bindels LB, Beck R, Schakman O., Martin JC, De BF, Sohet FM et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS ONE 2012; 7: e37971.
174. Heppner KM, Piechowski CL, Muller A, Ottaway N., Sisley S, Smiley DL et al. Both acyl and des-acyl ghrelin regulate adiposity and glucose metabolism via central nervous system ghrelin receptors. Diabetes 2014; 63: 122-131.
175. St-Pierre D.H., Karelis AD, Cianflone K, Conus F., Mignault D, Rabasa-Lhoret R et al. Relationship between ghrelin and energy expenditure in healthy young women. J Clin Endocrinol Metab 2004; 89: 5993-5997.
176. Porporato PE, Filigheddu N, Reano S., Ferrara M, Angelino E, Gnocchi VF et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013; 123: 611-622.
177. Ruozi G, Bortolotti F, Falcione A., Dal Ferro M, Ukovich L, Macedo A et al. AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia. Nat Commun 2015; 6: 7388.
178. Filigheddu N, Gnocchi VF, Coscia M, Cappelli M., Porporato PE, Taulli R et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell 2007; 18: 986-994.
179. Garcia JM, Boccia RV, Graham C.D., Yan Y., Duus EM, Allen S et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2015; 16: 108-116.
180. Al-Zoughbi W., Huang J, Paramasivan G.S., Till H., Pichler M, Guertl-Lackner B et al. Tumor macroenvironment and metabolism. Semin Oncol 2014; 41: 281-295.
181. Mayers JR, Wu C, Clish C.B., Kraft P., Torrence ME, Fiske BP et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 2014; 20: 1193-1198.
182. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
183. Carmeliet P, Jain RK Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
184. Porporato PE, Dhup S, Dadhich R.K., Copetti T., Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2: 49.
185. De Saedeleer C.J., Porporato PE, Copetti T, Perez-Escuredo J, Payen V.L., Brisson L et al. Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration. Oncogene 2014; 33: 4060-4068.
186. Lewis CA, Brault C, Peck B., Bensaad K, Griffiths B, Mitter R et al. SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene 2015; 34: 5128-5140.
187. Nieman KM, Kenny HA, Penicka C.V., Ladanyi A., Buell-Gutbrod R, Zillhardt MR et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17: 1498-1503.
188. Tonjes M, Barbus S, Park Y.J., Wang W., Schlotter M, Lindroth AM et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 2013; 19: 901-908.
189. Son J, Lyssiotis CA, Ying H, Wang X., Hua S, Ligorio M et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-105.
190. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
191. Maddocks OD, Berkers CR, Mason S.M., Zheng L., Blyth K, Gottlieb E et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013; 493: 542-546.
192. Luo Y, Yoneda J, Ohmori H., Sasaki T, Shimbo K, Eto S et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res 2014; 74: 330-340.
193. Taguchi A, Blood DC, del T.G., Canet A., Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
194. Yan HX, Wu HP, Zhang H.L., Ashton C., Tong C, Wu H et al. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013; 59: 762-768.
195. Tabata C, Shibata E, Tabata R., Kanemura S, Mikami K, Nogi Y et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 2013; 13: 205.
196. Theologides A. Cancer cachexia. Cancer 1979; 43(Suppl 5): 2004-2012.
197. Fearon K, Strasser F, Anker S.D., Bosaeus I., Bruera E, Fainsinger RL et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495.